Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jacobsen

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Nature Medicine|November 15, 2024
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Blood Advances|October 31, 2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortiumJessy Xinyi Han, Min Jung Koh, Leora Boussi, et al.
British Journal of Haematology|May 1, 2025
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium studyMark N Sorial, Jessy Xinyi Han, Min Jung Koh, et al.
Leukemia & Lymphoma|March 14, 2026
Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global ConsortiumColin J Thomas, Min Jung Koh, Omar Elghawy, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Nature Medicine|November 15, 2024
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Blood Advances|October 31, 2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortiumJessy Xinyi Han, Min Jung Koh, Leora Boussi, et al.
British Journal of Haematology|May 1, 2025
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium studyMark N Sorial, Jessy Xinyi Han, Min Jung Koh, et al.
Leukemia & Lymphoma|March 14, 2026
Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global ConsortiumColin J Thomas, Min Jung Koh, Omar Elghawy, et al.
Pageof 7